Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-24-006 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 16, 2023 Category: Research Source Type: funding
The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)
Funding Opportunity PAR-21-348 from the NIH Guide for Grants and Contracts. The role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection and AIDS will increase our understanding through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression and the resulting disease sequelae. In addition, insights into mechanistic differences of EBV infection and lymphomagenesis between HIV positive and HIV negative persons will be gained. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 27, 2021 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-20-046 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and ot...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 23, 2020 Category: Research Source Type: funding
Genomic Data Analysis Network: Genomic Data Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-20-053 from the NIH Guide for Grants and Contracts. Projects to be Served by Pipeline The proposed analytical network will serve to understand the data generated by CCG programs as well as collaborations with other divisions: The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) Exceptional Responders (ER, in collaboration with DCTD) Clinical Trials Sequencing Program (CTSP, in collaboration with DCTD) Carcinomas of Unknown Primary (CUPP) Refractory Cancers (Peripheral T-Cell Lymphomas, Recurrent GBMs) This resource that can be utilized by any NCI p...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 4, 2020 Category: Research Source Type: funding
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Funding Opportunity RFA-CA-19-056 from the NIH Guide for Grants and Contracts. The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2019 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-18-014 from the NIH Guide for Grants and Contracts. The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of develop...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 10, 2018 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-18-013 from the NIH Guide for Grants and Contracts. The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of develop...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 10, 2018 Category: Research Source Type: funding
Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp)
Funding Opportunity Number: PA-16-086 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.39493.39593.397Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) ...
Source: Grants.gov - January 21, 2016 Category: Research Tags: Education Health Source Type: funding
Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp)
Funding Opportunity PA-16-086 from the NIH Guide for Grants and Contracts. The Center for Global Health (CGH) at the National Cancer Institute (NCI) seeks to promote clinical research studies on pediatric Burkitt Lymphoma (BL) in low- and middle-income countries (LMICs) through collaborations and research partnerships between NCI-designated Cancer Centers and partner institutions in LMICs. Through this funding opportunity announcement (FOA), the NCI will provide administrative supplement awards to currently funded P30 NCI-designated Cancer Center grants to support pilot research projects on pediatric BL. These partn...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 19, 2016 Category: Research Source Type: funding
Request for Proposals: Leukemia & Lymphoma Society Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers
Request for Proposals: Leukemia & Lymphoma Society Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers The Leukemia & Lymphoma Society (LLS) is proud to announce the "Transforming CURES Initiative (TCI) - Intercepting Progression to Advanced Myeloid Blood Cancers," a new Request for Proposals (RFP) to identify and develop novel, safe and effective treatment paradigms for patients with hematological malignancies. The near term goal of this program is to advance the scientific and medical understanding of myeloid disease progression from an early stage to fra...
Source: ScanGrants feed - November 17, 2014 Category: Research Authors: Leukemia & Lymphoma Society Source Type: funding
Lymphoma Clinical Research Mentoring Program
A Training Program for Hematology/Oncology Fellows and Junior Faculty with a focus on Clinical Research in Lymphoma Application Receipt Date: Extended Deadline – 5 PM EST September 24, 2014 The Lymphoma Research Foundation (LRF) Lymphoma Clinical Research Mentoring Program (LCRMP) is an education and mentoring program for fellows and junior faculty with a focus in clinical research in the field of non-Hodgkin and Hodgkin lymphoma. The program is two years in length and offers a broad education on clinical research and career development as well as managing career and quality of life issues. The goals of ...
Source: ScanGrants feed - September 10, 2014 Category: Research Authors: Lymphoma Research Foundation Source Type: funding
Limited Competition: AIDS Malignancy Clinical Trials Consortium (UM1)
Funding Opportunity Number: RFA-CA-14-502 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: EducationHealthCFDA Number: 93.39393.39493.39593.396Eligible Applicants Others (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-NIH11Closing Date: Jan 06, 2015Award Ceiling: $21,400,000Expected Number of Awards: 1Creation Date: Aug 08, 2014Funding Opportunity Description: The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the re...
Source: Grants.gov - August 9, 2014 Category: Research Tags: Education Health Source Type: funding
Limited Competition: AIDS Malignancy Clinical Trials Consortium (UM1)
Funding Opportunity RFA-CA-14-502 from the NIH Guide for Grants and Contracts. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of the AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 8, 2014 Category: Research Source Type: funding
Request for Proposals: Lymphoma Research Foundation Grant Program
The Lymphoma Research Foundation (LRF) announces Requests for Proposals (RFP) on a regular basis each year. In calendar year 2014, LRF is offering the three Young Investigator Grant programs, as well as a Disease Focus Area Correlative Grant in Adolescent/Young Adult Lymphomas. Questions about LRF's funding opportunities may be directed to researchgrants@lymphoma.org. Now Open: 2015 Grant Applications Application Deadline: 5:00 pm EST September 3, 2014 Young Investigator Grants Clinical Investigator Career Development Award Postdoctoral Fellowship Grant Lymphoma Clinical Research Mentor...
Source: ScanGrants feed - June 10, 2014 Category: Research Authors: Lymphoma Research Foundation Source Type: funding
Leukemia & Lymphoma Society Quest for Cures Request for Proposals
Leukemia & Lymphoma Society Quest for Cures Request for Proposals Letter of Intent Deadline: June 3, 2014, 3:00 PM ET This RFP represents a new LLS research grant paradigm; QFC projects should, if successful, have a measurable impact on the diagnosis or treatment of patients with hematologic malignancies over the next 5 to 10 years. Proposals must include specific timelines, milestones and deliverables that researchers believe are achievable with their proposed funding. The range of funding available is from $200,000 to $400,000 annually, for research to be completed in a period of 2 years. Additional fund...
Source: ScanGrants feed - May 1, 2014 Category: Research Authors: Leukemia & Lymphoma Society Source Type: funding
